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Abstract Periostin is a member of a growing family of
matricellular proteins, defined by their ability to interact with
components of the extracellular milieu, and with receptors at
the cellsurface.Throughthese interactions,periostinhas been
shown to play a crucial role as a profibrogenic molecule
during tissue morphogenesis. Tissues destined to become
fibrous structures are dependent on cooperative interactions
between periostin and its binding partners, whereas in its
absence, these structures either totally or partially fail to
become mature fibrous entities. Within the heart, fibrogenic
differentiation is required for normal tissue maturation,
remodeling and function, as well as in response to a
pathological myocardial insult. In this review, aspects related
to the function of periostin during cardiac morphogenesis,
remodeling and pathology are summarized.
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Abbreviations
α-SMA α-Smooth Muscle Actin
AV Atrioventricular
βigH3 TGFβ-induced gene-Human Clone 3
BMP Bone Morphogenetic Protein
DDR2 Discoidin Domain Receptor-2
ECM Extracellular Matrix
ED Embryonic Day
EDS Ehlers-Danlos Syndrome
EPDC Epicardial-Derived Cell
FAK Focal Adhesion Kinase
HSPG Heparin Sulfate Proteoglycan
MHC Myosin Heavy Chain
MLC Myosin Light Chain
OFT Outflow Tract
OSF-2 Osteoblast Specific Factor-2
PLF Periostin-Like Factor
ROCK Rho Kinase
SPARC Secreted Protein, Acidic, Rich in Cysteine
SRF Serum Response Factor
VEGF Vascular Endothelial Growth Factor
YY1 Yin Yang-1
Introduction
The periostingenewasinitiallyclonedfroma mouse calvarial
cell line (MC3T3-E1) and originally named osteoblast
specific factor-2 (OSF-2) (Takeshita et al. 1993). This name
was eventually changed to “periostin” due to its intense
expression within the periosteum and periodontal ligament
as well as to avoid any confusion with a transcription factor
with the same name (Ducy et al. 1997;H o r i u c h ie ta l .1999).
The encoded periostin protein has a molecular weight of
~90 kDa and contains four domains that are highly related in
amino acid sequence to the ancestral fasciclin gene in
Drosophila (Horiuchi et al. 1999).
Periostin is one of four known mammalian genes that
contain fasciclin domains. The other fasciclin genes are:
TGFβ-Induced Gene-Human clone 3 (a.k.a βigH3) (Skonier
et al. 1992), as well as stabilin 1 and 2 (Politz et al. 2002).
βigH3 shares 49% overall amino acid homology (70%
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Periostin protein has a signal sequence (targeting it for
secretion), four-coiled fasciclin-like repeats, an amino-
terminal cysteine-rich region (EMI domain), and heparin-
binding domains present in the carboxyl tail. Although the
domains for periostin have been described based on
sequence homology, it is still unclear as to the function of
each of these domains. Interestingly, Western analysis and
genomic sequencing have revealed that as many as six
carboxyl splice variants may be produced from the periostin
locus (Litvin et al. 2004; Shimazaki et al. 2008). One of
these variants has been termed “Periostin-like Factor” or
“PLF”, which itself is not a separate member of the fasciclin
gene family as the name would imply, but rather is one of
the naturally occurring splice variants from the periostin
locus (Litvin et al. 2004).
Data ascribing function to these unique variants has only
begun to be examined. As isoform-specific expression has
been found in a variety of cell and tissue types, a more
comprehensive understanding of periostin variant function
will undoubtedly yield new insight into developmental and
pathological processes. Whereas periostin clearly has major
roles in both tooth development (Kii et al. 2006) and cancer
(Ruan et al. 2009), for the purpose of this review we will
focus on findings related to the current understanding of
periostin during cardiac development and pathology, as
well as the known molecular mechanisms by which it elicits
these activities.
Expression of periostin during cardiac development
The expression of periostin during chick and mouse cardiac
development has been examined, with the mouse patterns
more thoroughly studied (Kern et al. 2005; Kruzynska-
Frejtag et al. 2001; Lindsley et al. 2005; Norris et al. 2004,
2005, 2008b). To date, no difference in expression patterns
have been detected between the two species except in the
mural leaflet of the tricuspid valve, where the avian system
has a muscular/myocardial leaflet (and no periostin expres-
sion) in lieu of a fibrous leaflet as seen in the mouse.
During cardiac morphogenesis, periostin is expressed
primarily by mesenchymal tissues that will give rise to the
atrioventricular and outflow (semilunar) valve leaflets, the
annulus fibrosae, chordae tendineae, and ventricular fibro-
blasts. Here, we focus on specific expression of periostin
within these structures.
Periostin protein is first detected within mesenchyme of
the atrioventricular (AV) canal that is formed by the
transformation of endothelial cells into mesenchyme
(EMT) beginning at embryonic day (ED) 9.5 (Norris et al.
2008b). As EMT progresses, periostin expression, initially
cytoplasmic, becomes predominantly extracellular as the
mesenchyme of the AV canal (junction) expands between
ED 10 and 12.5 to form “endocardial cushions”,t h e
primordia of future valves and septa. Mesenchymalized
cushions also form in the proximal and distal regions of
outflow tract (OT) cushions between ED 10.5 and ED12.5.
In the outflow tract cushions, periostin is expressed by both
endothelial-derived mesenchyme as well as by neural crest
cells (Lindsley et al. 2007; Norris et al. 2008b). Distally the
OT cushions develop into the aortic and pulmonary
(semilunar) valve leaflets during which time (E13.5 and
E16) they strongly express periostin. Expression within the
aortic valve appears to be widespread throughout the
leaflet, whereas the pulmonary valve exhibits more intense
expression on the ventricular aspect of the leaflet. Weak
expression is also evident within the wall of the aorta and
the anterior aspect of the interventricular septum, in the
ventral mesenchyme of the fused AV cushions. The
developing mitral and tricuspid AV valves also exhibit
intense periostin staining from E13.5 through E16. Addi-
tionally, periostin is expressed in the epicardial epithelium
at E13.5 and in epicardially-derived mesenchymal cells that
also are generated by EMT. Some epicardially-derived cells
(EPDC) migrate into the myocardial wall and differentiate
into interstitial fibroblasts. Other EPDCs remain within a
groove or sulcus that completely encircles the external
surface of the AV junction at E16.
Over time, the AV junctional myocardium is lost
and the sulcus (EPDC) mesenchyme directly contacts
endocardially-derived cushion mesenchyme. Both popula-
tions of mesenchyme intensely express periostin: the EPDC
sulcus mesenchyme becomes the fibrous annulus which
serves to anchor the base of the mitral and tricuspid valve
leaflets derived from AVendocardial cushion mesenchyme.
Additionally, strands of periostin protein are seen extending
caudally from the base of the interventricular septum to its
apex (Norris et al. 2008b). This pattern of expression in the
septum coincides with the left and right bundle branches of
the central AV conduction system. Just after birth, neonatal
expression of periostin intensifies in the interstitial fibro-
blastic cells of the myocardial wall and in both inlet (AV)
and OT valves, which do not complete their morphogenesis
until after birth (Borg and Markwald 2007; Norris et al.
2008b; Oka et al. 2007). Periostin is also expressed in the
tendinous supporting structures (chordae tendineae) of the
AV valves. In the adult mouse, periostin expression
continues for life, being most intensely expressed within
the chordae tendineae, fibrous annulus and AV and arterial
valves (Fig. 1). Expression in all leaflets is more predom-
inantly confined to the ventricular aspects of the leaflets,
i.e. the surface where sheer stress is greatest. After the
neonatal period, periostin expression diminishes in the
myocardial walls.
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periostin may function to promote the differentiation of
mesenchymal tissues into mature fibroblastic structures
(Norris et al. 2008b). This is based on expression data
showing that the highest levels of periostin are found in
mesenchymal tissues (derived by an EMT process) that are
fated to become fibrous structures (e.g. valve leaflets,
chordae tendineae, ventricular fibroblasts). Data generated
from gain and loss of function experiments would later add
significant insight into the validity of this hypothesis.
Gain and loss of function: the dynamic role of periostin
during cardiac development
To date, three periostin knockout mice have been generated
with each showing similar phenotypes (Kii et al. 2006;
Norris et al. 2007; Oka et al. 2007; Rios et al. 2005). The
majority of knockout mice are viable and smaller on
average than littermate control animals. Approximately
20% appear to die either early in development or during
the neonatal period. A close examination of the cardiac
structures in which periostin was expressed yielded new
and intriguing insight into not only the function of periostin
during heart development, but also in key differentiation
processes guiding proper valve maturation.
The AV and OFT cushions in the periostin knockout
mice appear to undergo both endocardial and epicardial
EMT as mesenchymal cells are clearly present within the
cushions at later stages of development, indicating that an
endothelial to mesenchymal transformation had occurred
(Norris et al. 2008b; Snider et al. 2008). Most genes crucial
for EMT result in early embryonic lethality when geneti-
cally removed. The fact that most periostin-null mice live to
birth suggests that if periostin has a role in valvulogenesis,
it would be during the “post-EMT” morphogenesis of
cushions into valve leaflets. Thus, the morphological
development of the valves following this initial EMT
period (so-called “Post-EMT”) in the periostin knockout
animals was analyzed by two independent groups (Norris et
al. 2008b; Snider et al. 2008). The findings demonstrated
that periostin-null mice exhibit a primary defect in the
differentiation of valve mesenchymal precursor cells into
fibroblasts. The outcome of abnormal differentiation was
altered morphogenesis of the leaflets and their supporting
apparatus, as well as retention of myocardial structures that
normally regress or are lost.
Periostin regulates differentiation of valve leaflet
progenitor cells
As demonstrated by Norris et al (Norris et al. 2008b) and
subsequently confirmed by Snider et al (Snider et al. 2008),
a subpopulation of cushion mesenchyme in the periostin-
null mice aberrantly differentiate into MF20/myosin heavy
chain (MHC) positive myocytes. This finding was further
tested in vitro and it was demonstrated that periostin-
knockout cushion mesenchymal cells express myocardial
markers, MHC and MF20 (sarcomeric myosin), whereas
wild-type cells fail to express these markers. Addition of
purified periostin to these cultures reduced the expression
of myocardial markers, indicating that periostin is required
for the inhibition of a myocardial gene program in
prevalvular mesenchymal cells.
Further evidence for periostin functioning in an anti-
myocardial pathway was recently presented. In a report by
Niu et al. (2008), serum response factor (SRF) was shown
to repress Gata-6 and periostin expression in early
cardiogenic mesoderm. Conditional ablation of SRF in
early cardiogenic mesoderm (that normally differentiates
into cardiac muscle) induced the expression of periostin and
Gata-6. Additionally, this report demonstrated that the
epicardium of periostin-null mice had ectopic pockets, or
foci, of MHC-positive cells suggesting aberrant epicardial
to myocardial differentiation (Niu et al. 2008). In addition
to a role for periostin in blocking myocardial differentia-
tion, it has recently been demonstrated that endocardially-
cushion mesenchyme from periostin-null mice exhibit
decreased levels of collagen I, a characteristic of cells that
differentiate into fibroblasts (Norris et al. 2008b). Null-
cushion cells also were devoid of the collagen receptor,
DDR2 (Discoidin Domain-2), which has been shown to be
a cardiac fibroblast marker and functions as an important
regulator of collagen fibrillogenesis (Norris et al. 2007).
Fig. 1 Expression of periostin in the adult murine tricuspid valve.
Immunohistochemical staining of Periostin (green) in the adult murine
tricuspid valve leaflet showing robust staining in the chordae
tendineae (CT) and valve leaflet. Expression of periostin in non-
fibrous tissue (papillary muscle-PM) is negligible
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DDR2 and collagen deficit, demonstrating that periostin
can promote fibrogenesis through a DDR2/collagen path-
way. Consistent with periostin being a matricellular protein,
periostin has been shown to bind to collagen during
fibrillogenesis, thus affecting the diameter of collagen
fibers and cross-linking (Kii et al. 2006; Norris et al.
2007; Shimazaki et al. 2008).
The potential for periostin to block myocardial differen-
tiation while promoting fibrogenesis was further evaluated
in the chick (Norris et al. 2009). In this system, AV cushion
mesenchyme was isolated and tested in hanging drop and
novel cardiotube assays. Expression levels of perisotin were
manipulated using specific adenoviruses (anti-sense and
over-expression). Consistent with the previous mouse
reports, it was found that inhibiting periostin in chick AV
mesenchyme not only decreased collagen expression, but
also induced myocardial markers (MHC, MLC, and
desmin). The mechanism(s) by which periostin may elicit
its profibrogenic and anti-myocardial effect on mesenchy-
mal cell differentiation is currently unknown, but clearly
suggests roles for SRF, DDR2, collagen, and specific
integrin receptors (as discussed later).
Periostin is required for fibrous maturation of AV
leaflets and their supporting structures
As described above, the role of periostin during valve
development appears to be primarily in promoting the
differentiation of mesenchymal cells into fibroblasts. In its
absence (loss of function) this same population of mesenchy-
mal cells acquires the potential to differentiate into other
mesodermal lineages (e.g. cardiac myocytes), demonstrating
that AV cushion mesenchyme is multipotential but normally
becomes fibroblastic in the presence of periostin. As cushion
mesenchyme and epicardially-derived mesenchyme provide a
morphogenetic blueprint for the future valve leaflets, it is
interestingtonotethattheadultatrioventricularvalvesdisplay
similar differentiation defects, as did the embryonic tissues,
suggesting a continuation and amplification of these devel-
opmental anomalies.
Adult periostin-null mitral and tricuspid leaflets exhibit a
significant reduction in collagen I protein with the coincident
presence of excessive myocardial tissue, in addition to
aggrecan and proteoglycan accumulation (Norris et al.
2008b;S n i d e re ta l .2008). These defects, which are not
observed in normal valve leaflets, result in failure of proper
stratification, attenuation, and alignment of collagen, leading
over time to myxomatous valve degeneration and/or fibroe-
lastic deficiencies. Atomic force microscopy studies revealed
a smoother appearance and an increase in compliance
(decrease in stiffness) of the leaflet and chordal structures,
which would be expected with a fibroelastic deficiency.
Although it has not yet been examined, these changes in
leaflet structure and composition would be expected to
greatly influence the biomechanical properties of the leaflets,
which could lead to valve prolapse and retrograde blood
flow (regurgitation). In the periostin-null mouse, aortic
regurgitation has been seen.
Aside from the valve leaflets, defects in the fibrous
supporting structures were observed in periostin knockout
mice and in avian model systems (Kolditz et al. 2007;
Norris et al. 2008b). The two main structures affected are
the chordae tendineae and the annulus fibrosae. The
chordae tendineae anchor the ventricular aspect of the
leaflets to the myocardial wall via the papillary muscles and
are required for stability of the valve complex. Periostin-
knockout mice exhibit shortened chordae tendineae that
contain ectopic myocardial tissue, fail to branch during
postnatal life, and have an increase in chordal diameter.
Formation of the chordae tendineae is a complex process
that has not been thoroughly unraveled. It is hypothesized
that formation of the chordal complex is initiated by a
myocardial remodeling event near the shoulders of the base
of the ventricular wall (de la Cruz 1998).Intercellularspaces
appear within the myocardium of the free wall of the left and
right ventricle, adjacent to the leftand right lateral cushions of
the AV canal at the “myocardial shoulders”. These intercel-
lular spaces eventually coalesce and divide the myocardial
freewallintotwolayers:subepicardiumandsubendocaridum.
It is the subendocardial layer that is connected to the mural
leaflet and is later remodeled into the chordae tendineae and
papillary muscle. It is in these myocardial shoulders that
periostin expression is most abundant.
Periostin-null mice fail to remodel the AV junctional
tissue properly. The excavation of the myocardium, as is
normally seen, fails to occur and the formation of chordae
tendineae either does not occur, or the chords are truncated
and branching is diminished (Norris et al. 2008b). Addi-
tionally, delamination of the septal leaflet of the tricuspid
valve fails to occur. These defects in chordae size, in addition
to valvular dysplasia, would be expected to result in
displacement of the leaflets and their failure toproperlycoapt.
Although the mechanism is currently unknown, it is hypoth-
esized that periostin promotes the removal and coalescence of
this myocardial tissue by either inducing a transdifferentiation
of the myocardium or in promoting apoptosis. To date, there
has been no evidence that periostin promotes apoptosis of
myocardialtissue.Recently, datawerepresentedshowingthat
forced expression of periostin in cultured neonatal myocytes
promoted collagen gel invasion and smooth muscle marker
activation, substantiating a role for periostin in myocyte
transdifferentiation (Norris et al. 2008a).
Although the annulus fibrosae that anchors AV valve
leaflets and insulates atrial myocardium from ventricular
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models of periostin deficiency, elegant studies were
performed in the quail system. Kolditz et al. describe that
a delay in the formation and migration of the epicardium
results in persistence of accessory electrical pathways
(Kolditz et al. 2007). It is well established that these
accessory pathways, which can cause arrhythmias in
humans (e.g. Wolff-Parkinson-White syndrome), consist
of abnormal cardiac musculature that crosses the AV
groove/sulcus (Becker et al. 1978). By using this model
system in chick it was discovered that the epicardium-
derived cells traveling through the atrioventricular border
via the AV sulcus are crucial for proper annulus formation
and electrical isolation. As these cells migrate they
abundantly express periostin and collagen. A delay in the
formation of the epicardium resulted in failure to form a
complete fibrous annulus, and was correlated with loss of
periostin expression at the AV junction and the persistence
of AV junctional myocardial cells. Retention of periostin
expression in AV junctional myocardial cells altered
electrophysiological features (short PR interval, slurring of
the QRS complex, and prolonged QRS), resulting in large
electrically-active accessory pathways transmitting through
the right and left lateral free wall. These results suggest that
epicardial delivery of periostin to the sulcus region of the
AV junction is required for sulcus cells to differentiate into
fibroblasts of the annulus, and in the absence of periostin,
myocardial retention occurs, resulting in electrophysiolog-
ical defects of the AV junctional myocardium.
Summary of valve development and maturation
Periostin has been described as the first matricellular protein
that functions as a hierarchical molecular switch to promote
the differentiation of mesenchymal cells into a fibroblastic
lineage,whilesuppressingtheirtransformationintomyocytes.
In addition, periostin may function to remodel junctional
myocardial tissue, a process indispensable for the formation
of the chordae tendineae and annulus fibrosae, by promoting
transdifferentiation (or apoptosis) of the resident myocytes.
Regardless of the mechanism, both chick and mouse data
promote the idea that periostin is a matricellular protein that
plays a unique role in valvulogenesis, and is necessary for the
proper morphogenesis and maturation of mesenchymal
tissues into their final fibrous structures.
Periostin functions to promote neonatal and ventricular
remodeling
Heart development does not end with birth. During the
postnatal period, the heart (valves and myocardial walls)
acquires its mature phenotype as it adapts to sudden
changes in systemic blood pressure (Guignard 1986; Jones
and Jose 2004; Kent et al. 2007a, b). These adaptive events,
often referred to as normal remodeling, are triggered by
biomechanical, electrical and chemical signals that result in
the sculpting and controlled growth (hypertrophy) of the
myocardial wall (Banerjee et al. 2006, 2007; Borg et al.
1984; Camelliti et al. 2005; Carver et al. 1991; Terracio et
al. 1990). Typically, normal neonatal remodeling is ob-
served as (i) an increase in fibroblast numbers (hyperplasia)
and new formation of fibrous ECM components, especially
collagen and (ii) hypertrophy of existing myocytes and their
subsequent exit from the cell cycle. Understanding the
function of specific genes expressed during this time of
active remodeling may provide clues as to how the heart
requires a specific genetic blueprint capable of sensing and
responding to changes in blood pressure.
Based on RT-PCR, Western analyses, and immunostain-
ing, it has been shown that periostin expression by
ventricular cardiac fibroblasts is abundant and peaks during
early neonatal life, subsequently declining to barely
detectable levels in adult life (Norris et al. 2008a; Oka et
al. 2007; Shimazaki et al. 2008). It is now thought that
periostin is important for the differentiation of precursor
cells into cardiac fibroblasts during the neonatal period.
This is based, in part, on flow cytometry data showing that
the neonatal periostin null-myocardium contains a signifi-
cant population of cells (30%) that cannot be identified by
standard markers that sufficiently identify >95% of the
cells in wild-type mice (Norris et al. 2008a). The reason for
this change in cell numbers is unknown but may be due to a
developmental defect in cardiac fibroblast progenitor cell
differentiation, migration, or both.
Understanding the role of periostin in this process of
normal neonatal ventricular remodeling may be applicable
to the study of adult remodeling following cardiac injury
since many of these developmental and/or neonatal pro-
grams are reactivated (“reawakened”). Following cardiac
injury in the adult, expression of periostin is highly
upregulated in resident fibroblasts associated with the
wound area, and has been shown to be important for the
scar formation process (Norris et al. 2008a; Oka et al. 2007;
Shimazaki et al. 2008). Periostin-null mice receiving a
myocardial infarction have an increased susceptibility to
cardiac rupture and exhibit decreased circumferential strain
and passive stiffness. However, periostin-null mice that
survive the initial myocardial insult were less susceptible to
fibrotic scarring and exhibited better ventricular perfor-
mance than wild-type controls. The mechanisms by which
this can be explained have recently begun to be examined.
The periostin-null mice exhibited reduced de novo collagen
synthesis and cross-linking, which resulted in frequent
cardiac rupture (Shimazaki et al. 2008). The overriding
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cells within the infarct, and an overall decrease in the
recruitment of cardiac fibroblasts to the infarct region. The
migration of these cells into the injury site appeared to be at
least partially dependent on FAK and downstream AKT
phosphorylation. The origin of the fibroblasts associated
with an injury site may stem not only from resident cardiac
fibroblasts, but also from the systemic circulation. Recent
studies have demonstrated that hematopoeitic stem cells
engraft into the heart following cardiac injury and express
high levels of periostin, presumably defining these cells as
differentiated cardiac fibroblasts (Visconti and Markwald
2006). Thus, if the role of periostin in heart development is
primarily to promote differentiation of mesenchymal
progenitor cells into fibroblasts while inhibiting differenti-
ation into alternative mesodermal lineages (e.g cardiomyo-
cyte), it is enticing to propose, that blocking or silencing
periostin expression in circulating progenitor cells follow-
ing cardiac injury may attenuate fibrous myocardial
remodeling by inducing (or redirecting) their differentiation
into a myocardial lineage. .
The potential for developing novel therapies for blocking
periostin expression may prove useful in tipping the
balance from fibroblast infiltration to that of myocardial
regrowth. In addition to this potential, data presented by
Kuhn et al. suggest that adding recombinant periostin in a
patch to the infracted area promotes proliferation of adult
cardiomyocytes (Kuhn et al. 2007). To date, this interesting
finding has not yet been corroborated by other groups
working with periostin. In fact, a recent effort to specifi-
cally determine if periostin promoted cell cycling in normal
or injured cardiomyocytes was not successful, suggesting
that the primary role for periostin is to promote fibroblastic
differentiation and not myocyte proliferation (Kuhn et
al. 2007).
Although these studies are in their infancy, it is
important to note the striking differences between primitive
species and mammals. For example, zebrafish and newts
are clearly capable of myocardial regeneration whereas in
mammals it is not readily evident (Ausoni and Sartore
2009). One explanation for this difference might be the
number and distribution of fibroblasts. Fibroblasts account
for the majority of nonmuscle cells in mammals but they
are rare in lower species and occur interspersed within the
subepicardial layer of the heart. This difference in cellular-
ity correlates with the increased hemodynamic load placed
on mammalian hearts after birth, which must be sustained
throughout life. Thus differences in biomechanical signal-
ing might induce more extracellular matrix-producing cells
(fibroblasts) in mammals. The near absence of fibroblasts in
newts, zebrafish, and salamanders may correlate with the
relative lack of periostin expression. Under such conditions
(as in null mice) an increased number of progenitor cells
that migrate into the heart may have differentiated into new
cardiomyocytes. Alternatively, reduced levels of periostin
may potentiate regeneration by promoting proliferation of
adult myocardial cells or their immediate precursors. By
trying to mimic such inhibition of periostin in mammals,
might this be a possible route to promoting or enhancing
myocardial regeneration?
Periostin functions as a matricellular protein
through specific cell-surface and matrix interactions
Intracellular signals respond to the periostin call
Unfolding the mechanisms by which periostin functions to
promote differentiation of endothelial or epicardially-
derived mesenchyme clearly invokes not only its interac-
tions with the extracellular milieu, but also with the cell
surface. It is through the specific interactions with αv/β3
and β1 that periostin functions to elicit important remodel-
ing of AV cushion mesenchyme (Butcher et al. 2006).
Stimulation of these receptors activates the PI-3 kinase and
Rho kinase (ROCK) pathways, which are essential for
promoting stress fiber and filipodia formation. Rho kinase,
a serine/threonine protein kinase, in conjunction with focal
adhesion kinase (FAK) stimulates adhesion and cell
migration by enhanced formation of filipodia. The mecha-
nisms by which periostin/integrin signaling induces these
responses are not known. One possibility suggested by
integrin-based signaling in other cell systems may involve
specific interactions between ROCK and the actin-binding
protein Filamin-A (Feng and Walsh 2004; Zhou et al.
2007). The small GTPase Rho, and its effector ROCK,
regulate actin cytoskeletal organization through specific
interactions with Filamin-A (Ohta et al. 2006; Ueda et al.
2003). These molecular interactions, in turn, are required
for stabilizing orthogonal actin networks required for
locomotion. It is interesting to note that Filamin-A can also
bind specifically to the cytoplasmic tails of the integrin
pairs shown to bind periostin (Kim et al. 2008). Thus it is
conceivable that periostin can stimulate movement of
filipodia via actin cytoskeletal remodeling that is mediated
through either a kinase-dependent (Rho and/or FAK) or -
independent (receptor-Filamin A mediated) events. It is
important to note that not only is the Rho pathway essential
for promoting migration and cell-shape changes via periostin
andFilamin-A,butithasalsobeenshownto:(i)blockmuscle
differentiation and (ii) mediate cardiac fibrosis in an
ischemic/reperfusion cardiomyopathy model by regulating
fibroblast precursor cell differentiation (Haudek et al. 2009).
Thus, in the context of the periostin-null mouse, decreased
expression or phosphorylation of Rho and/or FAK could be
anticipated to decrease cell migration and formation of
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differentiation.
In addition to migration and differentiation, valvular
precursor cells must also find a mechanism of remodeling
the surrounding matrix that is required for sculpting the
cushions into cusps and leaflets. Uncontrolled migration and
proliferationwouldundoubtedlyresultinavalveleafletwitha
randomized distribution of ECM components that would
correlate with impaired compaction/attenuation in sculpted
structures where shape dictates function. Thus, the leaflet
must continually remodel itself during embryonic and fetal
life to acquire the proper geometry. One way in which this
might occur isthrough the potential of valve precursor cells to
compact (and align) collagen fibers. It was recently shown
that cushion cells increase collagen compaction through a
periostin-dependent, integrin-based signaling mechanism,
originally demonstrated by Butcher et al. using the chick
system (Butcher et al. 2006). This finding was consistent
with the phenotype of the periostin-null mouse in which the
prevalvular cushions of knockout mice hearts were isolated
and placed in free-floating gels, where they exhibited a
phenotype in which there was significant reduction in
collagen compaction (Snider et al. 2008).
Though periostin, unlike βigH3, lacks a consensus RGD
integrin-binding motif, there are abundant data indicating
that periostin binds to specific integrin pairs. Depending on
the cellular and/or tissue context, periostin has been shown
to interact with integrins: αv, β3, β1, β5, and β4 (Baril et
al. 2007; Butcher et al. 2006; Gillan et al. 2002; Ruan et al.
2009). The specific periostin-integrin interaction domain
has yet to be fully characterized. However, the integrin-
binding domain for βigH3 has been mapped to the fasciclin
domains. Based on the high degree of sequence conserva-
tion between these two related proteins, specifically within
their fasciclin domains, we anticipate that these integrin-
binding motifs within periostin will also be discovered in
the fasciclin domains.
It is interesting to note that the matricellular proteins
periostin, βigH3, CCN1, and CCN2 are capable of
interacting with αv, β3, and β1 integrins and are each
expressed in the developing heart (Chen and Lau 2009;
Chuva de Sousa Lopes et al. 2004; Mo and Lau 2006;
Surveyor and Brigstock 1999). It is not known whether
there is competition among these proteins for the same
integrin pairs, or if specific heterodimeric or oligomeric
clusters of these proteins provide additional selectivity for
the various integrins. New findings demonstrating the
ability of periostin and βigH3 to specifically interact (via
their amino terminal EMI domains) would suggest cooper-
ation versus competition, although both possibilities persist
(Kim et al. 2009). The precise identification of the
periostin-integrin interacting regions will provide signifi-
cant insight into the mechanisms by which periostin
regulates integrin clustering and intracellular dynamics
including kinase signaling, cytoskeletal remodeling, cell
motility and collagen compaction. The intracellular signal-
ing cascades dependent on periostin signaling are only now
beginning to be examined in the context of early valvulo-
genesis and postnatal valve leaflet maturation. These initial
findings in cushion and valve progenitor cells, however,
already provide an important framework by which we can
advance our understanding of how matricellular proteins
like periostin can stimulate cell behavior, and ultimately
tissue structure. Moreover, it should be noted that other
receptor and membrane-bound complexes may, and prob-
ably do, interact with periostin. In fact, the carboxyl
terminus of periostin has been demonstrated to interact
with heparin (Sugiura et al. 1995). Thus, the possibility
remains that periostin can interact with cell-surface heparin
sulfate proteoglycans (HSPGs), such as the syndecans,
glypicans, perlecan, agrin, and/or collagen XVIII. These
interactions are currently unknown, but should be examined
as HSPGs are intricately involved in developmental and
disease processes.
Periostin and extracellular interactions
In addition to interacting with the cell membrane via
integrins, periostin also interacts with extracellular matrix
proteins including fibronectin, tenascin-C, βigH3, collagen
V, and collagen I (Kii et al. 2006; Kim et al. 2009; Norris et
al. 2007; Takayama et al. 2006). Due to the expression of
periostin in collagen- rich connective tissues, a majority of
the work focusing on periostin interactions has involved
periostin and collagen I. Intrinsic to these interactions are
the evolving roles that periostin plays in promoting
collagen fibrillogenesis (Norris et al. 2007). Collagen
fibrillogenesis is a multistep process that involves linear
and accelerative growth, followed by lateral growth and
subsequent fusion of collagen fibers (Canty and Kadler
2002; Canty and Kadler 2005; Kadler et al. 1996). Based
on studies of collagen fibrillogenesis in vitro, it has been
suggested that there is a correlation between collagen fibril
diameter and the mechanical properties of collagen-based
connective tissues (Christiansen et al. 2000). By altering
collagen diameter, the structural and functional integrity of
the connective tissue is compromised. Morphometric
studies of transmission electron micrographs demonstrated
a reduced diameter of collagen fibrils in periostin-knockout
mice compared to that in wild-type mice, indicating
changes in collagen fibril maturation and assembly (Norris
et al. 2007). These findings suggest that the binding of
periostin to collagen can serve to regulate the lateral
association of collagen microfibrils, thereby affecting fiber
diameter. This suggestion is further supported by two other
key findings: (i) periostin binds directly to collagen I and
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linking. These collagen interactions may be a common
function of matricellular proteins, as similar results have
been obtained in the context of SPARC-deficient animals
(Bradshaw et al. 2003).
The mechanisms by which SPARC affects collagen fibril
diameter also appear to be through the direct binding to
collagen type I. Additionally, SPARC is a substrate for
transglutaminase, an enzyme that catalyzes cross-links
between proteins (Aeschlimann et al. 1995). It is unclear
at the present time whether periostin is also a substrate for
transglutaminase or whether other enzymes, such as lysyl
oxidase, are involved in cross-linking collagen moieties.
Additional biomechanical assays have been used to more
fully appreciate the role of periostin in regulating and
maintaining proper biomechanics of collagen-rich, connec-
tive tissues. Overexpression of periostin in valve progenitor
cells (cushion mesenchyme) results in increased tissue
viscosity, as measured by using surface tensiometry and
tissue fusion assays. Whether this effect involves induction
of procollagen expression, enhanced fibril maturation and
stabilization, and/or resistance to the natural process of
collagen fibril turnover remains to be determined. In
addition, a variety of biophysical and biomechanical
experiments have demonstrated that collagen-rich connec-
tive tissues such as the skin, valve leaflet, and chordae
tendineae of periostin-null mice exhibit a decrease in
stiffness/compliance when compared to their wild-type
couterparts (Norris et al. 2007). The domain(s) in periostin
that bind collagen have not yet been determined but their
identification could prove critical for furthering our
understanding of collagen fibrillogenesis and fibrotic
processes.
Whereas the fasciclin and the carboxyl-terminal
alternatively-spliced domains have received much scientific
attention, the function of the amino-terminal end of the
protein is largely unstudied. This region of the protein
contains an EMI domain. The EMI domain, first named
after its presence in proteins of the Emilin family, is a small,
cysteine-rich module of around 75 amino acids (Doliana et
al. 2000). The EMI domain is found at the N-terminus of
specific extracellular proteins (βigH3, Periostin, and Emi-
lin’s) that are capable of multimer formation. Although no
direct interaction has been shown between Emilin family
members and periostin, it is noted that Emilin1 and
periostin co-localize within the developing heart, specifi-
cally in the forming valves and epicardium (Braghetta et al.
2002; Norris et al. 2004; Norris et al. 2008b). It has recently
been demonstrated that periostin and βigH3 heterodimerize
via their EMI domains (Kim et al. 2009). This interaction
was found to be essential for proper secretion of a periostin/
βigH3 dimer. One further significance of the EMI domain
is that this domain of Emilin1 inhibits TGFβ signaling by
binding to the proform of TGFβ precursors, and prevents
its maturation by furin convertases in the extracellular
space. In addition to valve morphogenesis, the discovery of
the EMI domain in periostin, with its function as a regulator
of TGFβ processing and activation points to its potential
importance in other adult disease processes, e.g. athero-
sclerosis, inflammation, tissue repair and fibrosis.
Regulation of periostin expression
Due to its clear importance in valve development and
cardiac remodeling, factors regulating periostin expression
are currently under investigation. To date, TGFβs 1, 2, and
3, BMPs 2 and 4, VEGF, CCN2, Vitamin-K, valsartan (an
angiotensin II antagonist), and interleukins 3, 4, 6 and 13
can all regulate periostin expression in a cell-specific
context (Asano et al. 2005; Banerjee et al. 2009; Blanchard
et al. 2008; Coutu et al. 2008; Iekushi et al. 2007; Inai et al.
2008; Norris et al. 2009; Shao and Guo 2004; Takayama et
al. 2006). As pertains to cardiac development, the TGFβs
and BMPs appear to be the main mediators of periostin
stimulation. In cushion mesenchyme, MEKK3 (mitogen-
activated protein/ERK kinase kinase-3) was shown to
stimulate TGFβ2 expression, which, in turn, activates
periostin expression and promotes EMT (Stevens et al.
2008). Additionally, it was found that TGFβ3 stimulation
of cushion mesenchymal cell explants in hanging drop
cultures resulted in an increase in periostin and collagen
expression, coincident with alterations in viscoelastic
properties (Norris et al. 2009). These findings suggest that
TGFβ stimulation of periostin expression results in the
deposition of matrix, which correlates with stages of valve
differentiation and maturation. It is not known whether
expression of periostin in cushion mesenchyme occurs
through the canonical Smad2/3 pathway or via the ERK/
MAP kinase pathway, although both pathways are likely
avenues for its regulation. BMP-2 has also been shown to
regulate periostin expression in cushion mesenchyme (Inai
et al. 2008). Through BMP-2 activation of the ALK6
receptor (a type I BMP receptor), Smad1/5/8 activation
occurs and the transcription factor Twist-1 is induced.
Twist1 is then capable of directly binding bind to, and
positively regulating the periostin promoter (Connerney et
al. 2006; Oshima et al. 2002; Vincentz et al. 2008). This, in
turn, stimulates cushion mesenchyme migration. These
responses can be abrogated by using a BMP-specific
inhibitor (noggin), or a dominant negative ALK6 virus.
Although the promoter of periostin has been sequenced,
and a number of conserved stretches identified, the only
transcription factors that have been identified to date in
regulating periostin expression in the heart are Twist1, SRF
(a negative regulator of periostin), and YY1 (Ying Yang-1)
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As YY1 is reported to be a ubiquitously expressed
transcription factor, it was striking that the periostin
promoter segment harboring the YY1 binding element in
transgenic mice only expressed the LacZ reporter gene in a
subset of cardiac cells. The reason for this is not known, but
probably involves a DNA-independent cardiac-specific co-
activator with which YY1 can cooperate. It is clear that
further studies are needed to identify specific promoter and
enhancer sequences capable of driving periostin expression
during development and disease. A schematic representa-
tion of the current understanding of periostin’s effect on the
molecular regulation and differentiation of mesenchymal
cells (valve progenitor cells) is depicted in Fig. 2.
Fig. 2 Periostin molecular regulatory networks in fibroblast progen-
itor cells. MEKK stimulates TGFβ2 production (I) which is secreted
and stimulates its canonical receptor (IIa) This stimulates downstream
Smad phosphorylation and activation, which targets these proteins to
the nucleus where they cooperate with cell-specific transcription
factors to regulate the periostin promoter. It is not known whether
these phospho-Smad proteins cooperate with Twist1, YY1, or SRF
(known transcriptional regulators of periostin expression) to promote
or repress periostin transcription. BMP2/4 (IIb) are known to act
through the Smad 1/5/8 pathway to activate Twist1 and stimulate
periostin expression. Periostin is secreted, after which it can interact
with specific cell-surface receptors (III). In doing so, they stimulate
intracellular signal cascades which involve, among other, PI3-Kinase
and Rho kinase. This stimulates filipodia and actin reorganization
(stress fiber formation) to mediate migration, adhesion, and fibroblast
differentiation. Secreted periostin additionally regulates collagen
fibrillogenesis via a promotion of collagen cross-linking (IV).
Through these combined matricellular functions (receptor-mediated
cell signaling and matrix interactions), periostin regulates the
differentiation, maturation, and biomechanical properties of connec-
tive tissues, including skin, tendon, and heart valves
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Developmental defects in the ECM can have major
implications that over time greatly affect valve function.
Thus, even small changes in the composition (and
alignment) of the valvular ECM can affect valve differen-
tiation and ultimately compromise valve integrity, resulting
in valvular and cardiovascular diseases. This is evident in
Marfan Syndrome (Fibrillin-1 mutations), EDS (COL5A1,
COL5A2, and COL1A2 mutations with involvement of
tenascin-X, and COL1A1), and X-linked non-syndromic
mitral valve prolapse (Filamin-A mutations). It is important
to note that specific point mutations in these genes have
been identified and are expressed throughout cardiac
development. Indeed, we believe that there is not, nor
should there be, a defined line separating development
(including embryonic, fetal, neonatal) and adulthood.
Adulthood is clearly a result of developmental processes
acting in concert over time to form mature structures. Thus,
adulthood, in its very essence, is a continuum of develop-
mental processes. Of potential clinical relevance to peri-
ostin biology, EDS type II syndrome has been associated
with an unbalanced (6q; 13q) translocation which includes
the locus for periostin at 13q13.3 (Scarbrough et al. 1984).
In addition, patients with Rieger syndrome type II (who
have assorted cardiovascular malformations, such as: aortic
valvular stenosis, inter-atrial defects, congenital tricuspid
valve anomaly, bicuspid aortic valve, etc.) have been
assigned to chromosomal break points near the periostin
locus (Mammi et al. 1998; Phillips et al. 1996; Stathaco-
poulos et al. 1987). To date, no mutations in the periostin
gene have been identified as causal to a cardiac valvular
disease. However, based on the tight connection between
periostin and collagen, it would not be surprising to see
periostin play a significant contributing role in congenital
and/or acquired mitral and aortic valve disease.
Summary
Bornstein and colleagues have proposed that secreted
extracellular matrix proteins that function more in regula-
tion of cell-matrix interactions than as structural proteins
constitute a functionally-related family of proteins called
matricellular proteins (Bornstein 2000). Unlike structural
proteins such as collagen, laminins and elastin, matricel-
lular proteins derive their complex functions from their
ability to interact with multiple cell-surface receptors
(especially integrins), cytokines, growth factors, proteases,
and structural proteins. Examples of matricellular proteins
include thrombospondins, tenascin-C, osteopontin, CCN1,
SPARC, and periostin. The expression of this unique family
of ECM proteins is most prominent during development
and growth or in response to injury. Based on its known
biological roles as described in this review, we propose the
“Periostin Hypothesis” which defines this protein as a
crucial profibrogenic, anti-myocardial matricellular protein.
Implicit in this definition is periostin’s ability to promote
fibroblast differentiation while inhibiting myocardial
growth. Through its roles in growth factor stimulation,
matrix interactions, integrin-mediated signals, and biome-
chanical responsiveness, periostin is presented herein as a
“Maturagen” or a factor necessary for proper fibrous tissue
development and maturation during development, patho-
physiology, and disease.
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